Q3 Earnings Estimate for Zymeworks Issued By HC Wainwright

Zymeworks Inc. (NASDAQ:ZYME) – Analysts at HC Wainwright upped their Q3 2026 EPS estimates for Zymeworks in a research report issued on Monday, August 10th. HC Wainwright analyst R. Burns now forecasts that the company will earn $2.13 per share for the quarter, up from their previous forecast of $2.09. HC Wainwright has a “Buy” rating and a $51.00 price objective on the stock. The consensus estimate for Zymeworks’ current full-year earnings is $1.26 per share. HC Wainwright also issued estimates for Zymeworks’ Q4 2026 earnings at ($0.56) EPS and FY2027 earnings at ($1.72) EPS.

ZYME has been the topic of several other reports. Citigroup reiterated a “buy” rating on shares of Zymeworks in a research note on Monday. Truist Financial upped their price objective on Zymeworks from $31.00 to $32.00 and gave the stock a “buy” rating in a report on Friday, August 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Zymeworks in a research report on Friday, July 17th. Wells Fargo & Company upped their target price on Zymeworks from $37.00 to $40.00 and gave the stock an “overweight” rating in a research note on Friday. Finally, Stifel Nicolaus set a $46.00 price target on shares of Zymeworks in a research report on Friday. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $40.75.

Zymeworks Stock Performance

Shares of NASDAQ ZYME opened at $24.32 on Wednesday. Zymeworks has a fifty-two week low of $12.50 and a fifty-two week high of $29.75. The stock has a fifty day moving average of $23.99 and a 200-day moving average of $24.46. The stock has a market cap of $1.73 billion, a PE ratio of -12.04 and a beta of 1.15.

Zymeworks (NASDAQ:ZYME) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by ($0.06). Zymeworks had a negative net margin of 405.31% and a negative return on equity of 72.30%. The business had revenue of $4.59 million during the quarter, compared to the consensus estimate of $4.54 million. During the same period last year, the firm earned $0.03 EPS. The business’s revenue for the quarter was down 90.6% on a year-over-year basis.

Zymeworks announced that its board has authorized a stock repurchase plan on Thursday, May 14th that authorizes the company to repurchase $125.00 million in outstanding shares. This repurchase authorization authorizes the company to buy up to 7% of its stock through open market purchases. Stock repurchase plans are typically an indication that the company’s leadership believes its stock is undervalued.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Janney Montgomery Scott LLC grew its position in shares of Zymeworks by 3.8% in the 1st quarter. Janney Montgomery Scott LLC now owns 11,487 shares of the company’s stock worth $288,000 after buying an additional 420 shares during the last quarter. Tema ETFs LLC raised its holdings in shares of Zymeworks by 0.7% during the second quarter. Tema ETFs LLC now owns 105,615 shares of the company’s stock valued at $2,761,000 after acquiring an additional 684 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Zymeworks by 25.2% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,637 shares of the company’s stock valued at $96,000 after acquiring an additional 731 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its stake in Zymeworks by 10.4% in the first quarter. Allspring Global Investments Holdings LLC now owns 8,507 shares of the company’s stock worth $221,000 after acquiring an additional 800 shares during the period. Finally, Russell Investments Group Ltd. lifted its stake in Zymeworks by 1.6% in the fourth quarter. Russell Investments Group Ltd. now owns 58,350 shares of the company’s stock worth $1,536,000 after acquiring an additional 902 shares during the period. Hedge funds and other institutional investors own 92.89% of the company’s stock.

Trending Headlines about Zymeworks

Here are the key news stories impacting Zymeworks this week:

• Positive Sentiment: Theravance acquisition supports strategic growth. Theravance Biopharma reported second-quarter results in line with expectations and is set to be acquired by Zymeworks in a deal valued at approximately $929 million. The transaction follows Theravance’s cost-cutting efforts and discontinuation of ampreloxetine, and could strengthen Zymeworks’ portfolio of licensed healthcare assets. TBPH Meets Q2 Earnings Estimates, to be Acquired by Zymeworks
• Positive Sentiment: HC Wainwright maintained a bullish view. The firm reiterated its “Buy” rating and $51 price target, well above recent trading levels. The continued target support may reinforce investor confidence in Zymeworks’ asset and royalty strategy, despite projected losses in several 2027 quarters.
• Positive Sentiment: Upcoming conferences may improve investor visibility. Management plans to meet investors and hold fireside chats at Wells Fargo, Citi, Morgan Stanley and H.C. Wainwright conferences in September, providing opportunities to discuss Ziihera, pasritamig, the Theravance transaction and its broader biotherapeutics pipeline. Zymeworks Announces Participation in Upcoming Investor Conferences
• Neutral Sentiment: Short-interest data provides no usable signal. Reported short interest was zero on both the latest and prior reporting dates, with a zero-day days-to-cover ratio. Because the report also shows an invalid “NaN” percentage change, the figures should not be interpreted as evidence of changing bearish sentiment.
• Negative Sentiment: Analyst estimates were reduced. HC Wainwright lowered its FY2026 EPS forecast to $0.31 from $0.36, while forecasting losses of $0.45, $0.44, $0.42 and $0.42 per share for the first four quarters of 2027. Zymeworks’ recent results also showed a substantial year-over-year revenue decline and a quarterly EPS loss, highlighting execution and profitability risks.

Zymeworks Company Profile

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. The company specializes in engineered antibody and protein therapeutics designed to address a range of unmet medical needs in oncology and other serious diseases. Through its proprietary platforms, Zymeworks aims to create novel bispecific and multispecific molecules that can simultaneously engage multiple targets and recruit immune effector functions to enhance potency and specificity.

At the core of Zymeworks’ innovation is its Azymetric™ bispecific antibody platform, which enables the design of asymmetrical bispecific antibodies with controlled assembly and high stability.